Epigenetic treatment of neurological disease

Epigenomics

Volumn 3, Issue 4, 2011, Pages 431-450

  Gray, Steven G ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Alzheimer's disease; epigenetic modifiers; histone deacetylase; histone post translational modifications; Huntington's disease

Indexed keywords

4 PHENYLBUTYRIC ACID; ACYLTRANSFERASE; ALPHA TUBULIN; AMYLOID BETA PROTEIN; BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HUNTINGTIN; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLTRANSFERASE; RESVERATROL; TRICHOSTATIN A; UBIQUITIN PROTEIN LIGASE E3; VALPROATE SEMISODIUM; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BIPOLAR DISORDER; CAENORHABDITIS ELEGANS; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; COGNITIVE DEFECT; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; EPIGENETICS; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PHOSPHORYLATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SPINAL CORD INJURY; SURVIVAL;

ALZHEIMER DISEASE; BUTYLAMINES; CELL DIFFERENTIATION; ENDOPLASMIC RETICULUM STRESS; EPIGENESIS, GENETIC; HISTONE CODE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HUNTINGTON DISEASE; HYDROXAMIC ACIDS; NEURONS; PHENYLBUTYRATES; PROTEIN PROCESSING, POST-TRANSLATIONAL; STILBENES; VALPROIC ACID;

EID: 80051957020     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.11.67     Document Type: Review

References (249)

1. Walker FO. Huntington's disease. Lancet 369(9557), 218-228 (2007).
2. Gray SG. Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neurosci. Ther. 16(6), 348-361 (2010).
3. Ittner LM, Gotz J. Amyloid-b and t - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12(2), 65-72 (2011).
4. Allis CD, Berger SL, Cote J et al. New nomenclature for chromatin-modifying enzymes. Cell 131(4), 633-636 (2007).
5. Albert M, Helin K. Histone methyltransferases in cancer. Semin. Cell. Dev. Biol. 21(2), 209-220 (2010).
6. Sims RJ 3rd, Reinberg D. Is there a code embedded in proteins that is based on post-translational modifications? Nat. Rev. Mol. Cell Biol. 9(10), 815-820 (2008).
7. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. A pervasive role of histone acetyltransferases and deacetylases in an NF-kB-signaling code. Trends Biochem. Sci. 33(7), 339-349 (2008).
8. Gray SG. Targeting Huntington's disease through histone deacetylases. Clin. Epigenetics 2, DOI: org/10.1007/s13148-13011-10025-13147 (2011) (Epub ahead of print).
9. Zhang YQ, Sarge KD. Sumoylation of amyloid precursor protein negatively regulates Ab aggregate levels. Biochem. Biophys. Res. Comm. 374(4), 673-678 (2008).
10. Guan JS, Haggarty SJ, Giacometti E et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243), 55-60 (2009).
11. Bardai FH, D'Mello SR. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3b. J. Neurosci. 31(5), 1746-1751 (2011).
12. Yohrling GJ, Farrell LA, Hollenberg AN, Cha JH. Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol. Cell. Neurosci. 23(1), 28-38 (2003).
13. Duclot F, Meffre J, Jacquet C, Gongora C, Maurice T. Mice knock out for the histone acetyltransferase p300/CREB binding protein-associated factor develop a resistance to amyloid toxicity. Neuroscience 167(3), 850-863 (2010).
14. Francis YI, Fa M, Ashraf H et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimers Dis. 18(1), 131-139 (2009).
15. Saura CA, Choi SY, Beglopoulos V et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42(1), 23-36 (2004).
16. Bates EA, Victor M, Jones AK, Shi Y, Hart AC. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26(10), 2830-2838 (2006).
17. Sarkander HI, Fleischer-Lambropoulos H, Brade WP. A comparative study of histone acetylation in neuronal and glial nuclei enriched rat brain fractions. FEBS Lett. 52(1), 40-43 (1975).
18. Liu H, Hu Q, Kaufman A, D'ercole AJ, Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res. 86(3), 537-543 (2008).
19. Lakowski B, Roelens I, Jacob S. CoREST-like complexes regulate chromatin modification and neuronal gene expression. J. Mol. Neurosci. 29(3), 227-239 (2006).
20. Ajamian F, Suuronen T, Salminen A, Reeben M. Upregulation of class II histone deacetylases mRNA during neural differentiation of cultured rat hippocampal progenitor cells. Neurosci. Lett. 346(1-2), 57-60 (2003).
21. Horio Y, Hisahara S, Sakamoto J. [Functional analysis of SIR2]. Nippon Yakurigaku. Zasshi. (Suppl. 122) 30P-32P (2003).
22. Hoshino M, Tagawa K, Okuda T et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J. Neurochem. 87(1), 257-267 (2003).
23. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell. Mol. Life Sci. 60(9), 1990-1997 (2003).
24. Brunet A, Sweeney LB, Sturgill JF et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303(5666), 2011-2015 (2004).
25. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7(8), 847-854 (2004).
26. Renthal W, Maze I, Krishnan V et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56(3), 517-529 (2007).
27. Borovecki F, Lovrecic L, Zhou J et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl Acad. Sci. USA 102(31), 11023-11028 (2005).
28. Sadri-Vakili G, Bouzou B, Benn CL et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16(11), 1293-1306 (2007).
29. Stack EC, Del Signore SJ, Luthi-Carter R et al. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16(10), 1164-1175 (2007).
30. Lee J, Ryu H. Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? BMB Rep. 43(10), 649-655 (2010).
31. Chouliaras L, Rutten BP, Kenis G et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog. Neurobiol. 90(4), 498-510 (2010).
32. Ogawa O, Zhu X, Lee HG et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathol. 105(5), 524-528 (2003).
33. Ryan KA, Pimplikar SW. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell. Biol. 171(2), 327-335 (2005).
34. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl Acad. Sci. USA 106(43), 18367-18372 (2009).
35. Ohkawara T, Nagase H, Koh CS, Nakayama K. The amyloid precursor protein intracellular domain alters gene expression and induces neuron-specific apoptosis. Gene 475(1), 1-9 (2011).
36. Ghosal K, Stathopoulos A, Pimplikar SW. APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS ONE 5(7), e11866 (2010).
37. Cao X, Sudhof TC. Dissection of amyloid-b precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279(23), 24601-24611 (2004).
38. Xu X, Zhou H, Boyer TG. Mediator is a transducer of amyloid-precursor- protein-dependent nuclear signalling. EMBO Rep. 12(3), 216-222 (2011).
39. Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS ONE 4(12), e7936 (2009).
40. Qureshi IA, Gokhan S, Mehler MF. REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions. Cell Cycle 9(22), 4477-4486 (2010).
41. Bahn S, Mimmack M, Ryan M et al. Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study. Lancet 359(9303), 310-315 (2002).
42. Saijo K, Winner B, Carson CT et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137(1), 47-59 (2009).
43. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121(4), 645-657 (2005).
44. Battaglioli E, Andres ME, Rose DW et al. REST repression of neuronal genes requires components of the hSWI.SNF complex. J. Biol. Chem. 277(43), 41038-41045 (2002).
45. Watanabe H, Mizutani T, Haraguchi T et al. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25(3), 470-479 (2006).
46. Wang J, Scully K, Zhu X et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446(7138), 882-887 (2007).
47. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL. The bifunctional microRNA miR-9/miR-9. regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 28(53), 14341-14346 (2008).
48. Bithell A, Johnson R, Buckley NJ. Transcriptional dysregulation of coding and non-coding genes in cellular models of Huntington's disease. Biochem. Soc. Trans. 37(Pt 6), 1270-1275 (2009).
49. Zuccato C, Tartari M, Crotti A et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35(1), 76-83 (2003).
50. Conaco C, Otto S, Han JJ, Mandel G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc. Natl Acad. Sci. USA 103(7), 2422-2427 (2006).
51. Wu J, Xie X. Comparative sequence analysis reveals an intricate network among REST, CREB and miRNA in mediating neuronal gene expression. Genome. Biol. 7(9), R85 (2006).
52. Buckley NJ, Johnson R, Zuccato C, Bithell A, Cattaneo E. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol. Dis. 39(1), 28-39 (2010).
53. Johnson R, Richter N, Jauch R et al. The human accelerated region 1 noncoding RNA is repressed by REST in Huntington's disease. Physiol. Genomics (2010) (Epub ahead of print).
54. Lee ST, Chu K, Im WS et al. Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 227(1), 172-179 (2011).
55. Zhang J, Yang Y, Yang T et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br. J. Cancer 103(8), 1215-1220 (2010).
56. Quinti L, Chopra V, Rotili D et al. Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr. 2, pii: RRN1172 (2010).
57. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31(12), 605-617 (2010).
58. Boutillier AI, Trinh E, Loeffler JP. Constitutive repression of E2F1 transcriptional activity through HDAC proteins is essential for neuronal survival. Ann. NY Acad. Sci. 973, 438-442 (2002).
59. Pelegri C, Duran-Vilaregut J, Del Valle J et al. Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int. J. Dev. Neurosci. 26(7), 665-671 (2008).
60. Jordan-Sciutto Kl, Malaiyandi LM, Bowser R. Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. J. Neuropathol. Exp. Neurol. 61(4), 358-367 (2002).
61. Camelo S, Iglesias AH, Hwang D et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164(1-2), 10-21 (2005).
62. Curtis MA, Penney EB, Pearson AG et al. Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc. Natl Acad. Sci. USA 100(15), 9023-9027 (2003).
63. Lorincz MT, Zawistowski VA. Expanded CAG repeats in the murine Huntington's disease gene increases neuronal differentiation of embryonic and neural stem cells. Mol. Cell. Neurosci. 40(1), 1-13 (2009).
64. Lazarov O, Mattson MP, Peterson DA, Pimplikar SW, Van Praag H. When neurogenesis encounters aging and disease. Trends Neurosci. 33(12), 569-579 (2010).
65. Lopez-Toledano MA, Shelanski Ml. Increased neurogenesis in young transgenic mice overexpressing human APP (Sw, Ind).J. Alzheimers Dis. 12(3), 229-240 (2007).
66. Yu Y, He J, Zhang Y et al. Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 19(12), 1247-1253 (2009).
67. Macdonald JL, Roskams AJ. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev. Dyn. 237(8), 2256-2267 (2008).
68. Humphrey GW, Wang YH, Hirai T et al. Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation 76(4), 348-356 (2007).
69. Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl Acad. Sci. USA 106(19), 7876-7881 (2009).
70. Prozorovski T, Schulze-Topphoff U, Glumm R et al. Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat. Cell. Biol. 10(4), 385-394 (2008).
71. Sun G, Yu RT, Evans RM, Shi Y. Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc. Natl Acad. Sci. USA 104(39), 15282-15287 (2007).
72. Balasubramaniyan V, Boddeke E, Bakels R et al. Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience 143(4), 939-951 (2006).
73. Yao X, Zhang JR, Huang HR, Dai LC, Liu QJ, Zhang M. Histone deacetylase inhibitor promotes differentiation of embryonic stem cells into neural cells in adherent monoculture. Chin. Med. J. (Engl.) 123(6), 734-738 (2010).
74. Yu IT, Park JY, Kim SH, Lee JS, Kim YS, Son H. Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. Neuropharmacology 56(2), 473-480 (2009).
75. Lyssiotis CA, Walker J, Wu C, Kondo T, Schultz PG, Wu X. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc. Natl Acad. Sci. USA 104(38), 14982-14987 (2007).
76. Liu A, Han YR, Li J et al. The glial or neuronal fate choice of oligodendrocyte progenitors is modulated by their ability to acquire an epigenetic memory. J. Neurosci. 27(27), 7339-7343 (2007).
77. He Y, Dupree J, Wang J et al. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 55(2), 217-230 (2007).
78. Su X, Kameoka S, Lentz S, Majumder S. Activation of REST/NRSF target genes in neural stem cells is sufficient to cause neuronal differentiation. Mol. Cell. Biol. 24(18), 8018-8025 (2004).
79. Greenway DJ, Street M, Jeffries A, Buckley NJ. RE1 Silencing transcription factor maintains a repressive chromatin environment in embryonic hippocampal neural stem cells. Stem Cells 25(2), 354-363 (2007).
80. Sun YM, Greenway DJ, Johnson R et al. Distinct profiles of REST interactions with its target genes at different stages of neuronal development. Mol. Biol. Cell. 16(12), 5630-5638 (2005).
81. Gaub P, Tedeschi A, Puttagunta R, Nguyen T, Schmandke A, Di Giovanni S. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/ CAF-dependent p53 acetylation. Cell. Death Differ. 17(9), 1392-1408 (2010).
82. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature 447(7141), 178-182 (2007).
83. Hughes RE, Lo RS, Davis C et al. Altered transcription in yeast expressing expanded polyglutamine. Proc. Natl Acad. Sci. USA 98(23), 13201-13206 (2001).
84. Steffan JS, Bodai L, Pallos J et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857), 739-743 (2001).
85. Kegel KB, Meloni AR, Yi Y et al. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277(9), 7466-7476 (2002).
86. Ferrante RJ, Kubilus JK, Lee J et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23(28), 9418-9427 (2003).
87. Nuydens R, Heers C, Chadarevian A et al. Sodium butyrate induces aberrant t phosphorylation and programmed cell death in human neuroblastoma cells. Brain Res. 688(1-2), 86-94 (1995).
88. Kilgore M, Miller CA, Fass DM et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35(4), 870-880 (2010).
89. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. (2011) (Epub ahead of print).
90. Gardian G, Browne SE, Choi DK et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280(1), 556-563 (2005).
91. Ebbel EN, Leymarie N, Schiavo S et al. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/ electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal. Biochem. 399(2), 152-161 (2010).
92. Ricobaraza A, Cuadrado-Tejedor M, Perez-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces t pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34(7), 1721-1732 (2009).
93. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus DOI: 10.1002/hipo.20883 (2010) (Epub ahead of print).
94. Abematsu M, Tsujimura K, Yamano M et al. Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J. Clin. Invest. 120(9), 3255-3266 (2010).
95. Zadori D, Geisz A, Vamos E, Vecsei L, Klivenyi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol. Biochem. Behav. 94(1), 148-153 (2009).
96. Qing H, He G, Ly PT et al. Valproic acid inhibits Ab production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J. Exp. Med. 205(12), 2781-2789 (2008).
97. Salazar Z, Tschopp L, Calandra C, Micheli F. Pisa syndrome and parkinsonism secondary to valproic acid in Huntington's disease. Mov. Disord. 23(16), 2430-2431 (2008).
98. Venkataramani V, Rossner C, Iffland L et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the Alzheimer amyloid precursor protein. J. Biol. Chem. 285(14), 10678-10689 (2010).
99. Hockly E, Richon VM, Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100(4), 2041-2046 (2003).
100. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581-589 (2008).
101. Dokmanovic M, Perez G, Xu W et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6(9), 2525-2534 (2007).
102. Benn Cl, Butler R, Mariner L et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS ONE 4(6), e5747 (2009).
103. Dompierre JP, Godin JD, Charrin BC et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27(13), 3571-3583 (2007).
104. Perez M, Santa-Maria I, Gomez De Barreda E et al. t - an inhibitor of deacetylase HDAC6 function. J. Neurochem. 109(6), 1756-1766 (2009).
105. Jiang Q, Ren Y, Feng J. Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome. J. Neurosci. 28(48), 12993-13002 (2008).
106. Bonda DJ, Lee HG, Camins A et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 10(3), 275-279 (2011).
107. Richard T, Pawlus AD, Iglesias ML et al. Neuroprotective properties of resveratrol and derivatives. Ann. NY Acad. Sci. 1215, 103-108 (2011).
108. Thomas EA, Coppola G, Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105(40), 15564-15569 (2008).
109. Kozikowski AP, Chen Y, Subhasish T et al. Searching for disease modifiers - PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Ab production while blocking oxidative stress. Chem. Med. Chem. 4(7), 1095-1105 (2009).
110. Luthi-Carter R, Taylor DM, Pallos J et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc. Natl Acad. Sci. USA 107(17), 7927-7932 (2010).
111. Taylor DM, Balabadra U, Xiang Z et al. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem. Biol. 6(6), 540-546 (2011).
112. Arif M, Senapati P, Shandilya J, Kundu TK. Protein lysine acetylation in cellular function and its role in cancer manifestation. Biochim. Biophys. Acta. 1799(10-12), 702-716 (2010).
113. Hubbert C, Guardiola A, Shao R et al. HDAC6 is a microtubule-associated deacetylase. Nature 417(6887), 455-458 (2002).
114. Hempen B, Brion JP. Reduction of acetylated a-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55(9), 964-972 (1996).
115. Jeong H, Then F, Melia TJ Jr et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 137(1), 60-72 (2009).
116. Mankan AK, Lawless MW, Gray SG, Kelleher D, Mcmanus R. NF-kB regulation: the nuclear response. J. Cell. Mol. Med. 13(4), 631-643 (2009).
117. Thompson LM, Aiken CT, Kaltenbach LS et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell. Biol. 187(7), 1083-1099 (2009).
118. Cohen TJ, Guo JL, Hurtado DE et al. The acetylation of t inhibits its function and promotes pathological t aggregation. Nat. Comm. 2, 252 (2011).
119. Min SW, Cho SH, Zhou Y et al. Acetylation of t inhibits its degradation and contributes to tauopathy. Neuron 67(6), 953-966 (2010).
120. Kimura T, Fukuda T, Sahara N et al. Aggregation of detergent-insoluble t is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285(49), 38692-38699 (2010).
121. Stockley JH, O'Neill C. The proteins BACE1 and BACE2 and b-secretase activity in normal and Alzheimer's disease brain. Biochem. Soc. Trans. 35(Pt 3), 574-576 (2007).
122. Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the b-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem. 283(44), 29621-29625 (2008).
123. Faghihi MA, Modarresi F, Khalil AM et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of b-secretase. Nat. Med. 14(7), 723-730 (2008).
124. Costantini C, Ko MH, Jonas MC, Puglielli L. A reversible form of lysine acetylation in the ER and golgi lumen controls the molecular stabilization of BACE1. Biochem. J. 407(3), 383-395 (2007).
125. Ko MH, Puglielli L. Two endoplasmic reticulum (ER)/ER golgi intermediate compartment-based lysine acetyltransferases post-translationally regulate BACE1 levels. J. Biol. Chem. 284(4), 2482-2492 (2009).
126. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses b-amyloid production by activating the a-secretase gene ADAM10. Cell 142(2), 320-332 (2010).
127. Pallas M, Pizarro JG, Gutierrez-Cuesta J et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 154(4), 1388-1397 (2008).
128. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140(6), 883-899 (2010).
129. Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of immune, endocrine and metabolic disorders. Endocr. Metab. Imm. Disord. Drug Targets 9(1), 84-107 (2009).
130. Amor S, Puentes F, Baker D, Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology 129(2), 154-169 (2010).
131. Schwab C, Klegeris A, McGeer PL. Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim. Biophys. Acta 1802(10), 889-902 (2010).
132. Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting histone deacetylases for the treatment of disease. J. Cell. Mol. Med. 13(5), 826-852 (2009).
133. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkB kinase complex and nuclear factor-kB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 24(37), 7999-8008 (2004).
134. Khoshnan A, Ko J, Tescu S, Brundin P, Patterson PH. IKKa and IKKb regulation of DNA damage-induced cleavage of huntingtin. PLoS ONE 4(6), e5768 (2009).
135. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. NFkB-dependent control of BACE1 promoter transactivation by Ab42. J. Biol. Chem. 283(15), 10037-10047 (2008).
136. Tan L, Schedl P, Song HJ, Garza D, Konsolaki M. The Toll-NFkB signaling pathway mediates the neuropathological effects of the human Alzheimer's Ab42 polypeptide in Drosophila. PLoS ONE 3(12), e3966 (2008).
137. Chen J, Zhou Y, Mueller-Steiner S et al. SIRT1 protects against microglia-dependent amyloid-b toxicity through inhibiting NF-kB signaling. J. Biol. Chem. 280(48), 40364-40374 (2005).
138. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell. Biol. 14(1), 20-28 (2004).
139. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 87(4), 1377-1408 (2007).
140. Rapoport TA. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 450(7170), 663-669 (2007).
141. Bardag-Gorce F, Dedes J, French BA, Oliva JV, Li J, French SW. Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp. Mol. Pathol. 83(2), 160-168 (2007).
142. Ohoka N, Hattori T, Kitagawa M, Onozaki K, Hayashi H. Critical and functional regulation of CHOP (C/EBP homologous protein) through the N-terminal portion. J. Biol. Chem. 282(49), 35687-35694 (2007).
143. Donati G, Imbriano C, Mantovani R. Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters. Nucleic Acids Res. 34(10), 3116-3127 (2006).
144. Baumeister P, Luo S, Skarnes WC et al. Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol. Cell. Biol. 25(11), 4529-4540 (2005).
145. Cherasse Y, Chaveroux C, Jousse C et al. Role of the repressor JDP2 in the amino acid-regulated transcription of CHOP. FEBS Lett. 582(10), 1537-1541 (2008).
146. Vidal R, Caballero B, Couve A, Hetz C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. Curr. Mol. Med. 11(1), 1-12 (2011).
147. Reijonen S, Putkonen N, Norremolle A, Lindholm D, Korhonen L. Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins. Exp. Cell. Res. 314(5), 950-960 (2008).
148. Atwal RS, Truant R. A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy. Autophagy 4(1), 91-93 (2008).
149. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16(21), 2600-2615 (2007).
150. Yang H, Liu C, Zhong Y, Luo S, Monteiro MJ, Fang S. Huntingtin interacts with the cue domain of gp78 and inhibits gp78 binding to ubiquitin and p97/VCP. PLoS ONE 5(1), e8905 (2010).
151. Noh JY, Lee H, Song S et al. SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. J. Biol. Chem. 284(17), 11318-11325 (2009).
152. Carnemolla A, Fossale E, Agostoni E et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 284(27), 18167-18173 (2009).
153. Fossale E, Wheeler VC, Vrbanac V et al. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum. Mol. Genet. 11(19), 2233-2241 (2002).
154. Bennett EJ, Shaler TA, Woodman B et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448(7154), 704-708 (2007).
155. Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XI. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell. Biol. 180(6), 1177-1189 (2008).
156. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 12(2), 363-373 (2008).
157. Menendez-Benito V, Verhoef LG, Masucci MG, Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum. Mol. Genet. 14(19), 2787-2799 (2005).
158. Pandey UB, Nie Z, Batlevi Y et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447(7146), 859-863 (2007).
159. Lee JY, Koga H, Kawaguchi Y et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 29(5), 969-980 (2010).
160. Kawaguchi Y, Kovacs JJ, Mclaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727-738 (2003).
161. Boyault C, Zhang Y, Fritah S et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes. Dev. 21(17), 2172-2181 (2007).
162. Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes. Dev. 21(24), 3381-3394 (2007).
163. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell. Cycle 7(1), 7-10 (2008).
164. Riederer BM, Leuba G, Vernay A, Riederer IM. The role of the ubiquitin proteasome system in Alzheimer's disease. Exp. Biol. Med. (Maywood) 236(3), 268-276 (2011).
165. Gong B, Cao Z, Zheng P et al. Ubiquitin hydrolase Uch-L1 rescues b-amyloid-induced decreases in synaptic function and contextual memory. Cell 126(4), 775-788 (2006).
166. Hoozemans JJ, Veerhuis R, Van Haastert ES et al. The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathol. 110(2), 165-172 (2005).
167. Hoozemans JJ, Van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer's disease hippocampus. Am. J. Pathol. 174(4), 1241-1251 (2009).
168. Hoozemans JJ, Stieler J, Van Haastert ES et al. The unfolded protein response affects neuronal cell cycle protein expression: implications for Alzheimer's disease pathogenesis. Exp. Gerontol. 41(4), 380-386 (2006).
169. Copanaki E, Schurmann T, Eckert A et al. The amyloid precursor protein potentiates CHOP induction and cell death in response to ER Ca2+ depletion. Biochim. Biophys. Acta 1773(2), 157-165 (2007).
170. Takahashi K, Niidome T, Akaike A, Kihara T, Sugimoto H. Amyloid precursor protein promotes endoplasmic reticulum stress-induced cell death via C/EBP homologous protein-mediated pathway. J. Neurochem. 109(5), 1324-1337 (2009).
171. Nogalska A, Engel WK, Askanas V. Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers - possibly caused by endoplasmic reticulum stress. Neurosci. Lett. 474(3), 140-143 (2010).
172. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DF508-CFTR. Am. J. Physiol. Cell. Physiol. 278(2), C259-C267 (2000).
173. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant a 1-antitrypsin (a 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in a 1-AT deficiency. Proc. Natl Acad. Sci. USA 97(4), 1796-1801 (2000).
174. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66(4), 899-908 (2004).
175. Vilatoba M, Eckstein C, Bilbao G et al. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 138(2), 342-351 (2005).
176. Mulhern Ml, Madson CJ, Kador PF, Randazzo J, Shinohara T. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol. Vis. 13, 1397-1405 (2007).
177. Bonapace G, Waheed A, Shah GN, Sly WS. Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc. Natl Acad. Sci. USA 101(33), 12300-12305 (2004).
178. Ozcan U, Yilmaz E, Ozcan L et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of Type 2 diabetes. Science 313(5790), 1137-1140 (2006).
179. De Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, De Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J. Biol. Chem. 282(38), 27905-27912 (2007).
180. Kubota K, Niinuma Y, Kaneko M et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97(5), 1259-1268 (2006).
181. Wang JF, Bown C, Young LT. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol. Pharmacol. 55(3), 521-527 (1999).
182. Shao L, Sun X, Xu L, Young LT, Wang JF. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci. 78(12), 1317-1323 (2006).
183. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144(4), 1447-1453 (2007).
184. Boyault C, Gilquin B, Zhang Y et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J. 25(14), 3357-3366 (2006).
185. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, Yao TP. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell. Biol. 27(24), 8637-8647 (2007).
186. Kovacs JJ, Murphy PJ, Gaillard S et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell. 18(5), 601-607 (2005).
187. Bali P, Pranpat M, Bradner J et al. Inhibition histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280(29), 26729-26734 (2005).
188. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol. Cancer Ther. 6(9), 2515-2524 (2007).
189. Fiskus W, Ren Y, Mohapatra A et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-a levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer Res. 13(16), 4882-4890 (2007).
190. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1a. Mol. Cell. Biol. 26(6), 2019-2028 (2006).
191. Scroggins BT, Robzyk K, Wang D et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell. 25(1), 151-159 (2007).
192. Wang Y, Wang SY, Zhang XH et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Comm. 356(4), 998-1003 (2007).
193. Johnson CA, White DA, Lavender JS, O'Neill LP, Turner BM. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J. Biol. Chem. 277(11), 9590-9597 (2002).
194. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest. Ophthalmol. Vis. Sci. 48(4), 1683-1690 (2007).
195. Liu Xl, Done SC, Yan K, Kilpelainen P, Pikkarainen T, Tryggvason K. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J. Am. Soc. Nephrol. 15(7), 1731-1738 (2004).
196. Yam GH, Roth J, Zuber C. 4-Phenylbutyrate rescues trafficking incompetent mutant a-galactosidase A without restoring its functionality. Biochem. Biophys. Res. Comm. 360(2), 375-380 (2007).
197. Datta R, Waheed A, Shah GN, Sly WS. Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc. Natl Acad. Sci. USA 104(50), 19989-19994 (2007).
198. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes DF508 CFTR trafficking. Am. J. Physiol. Lung. Cell. Mol. Physiol. 281(1), L58-L68 (2001).
199. Cheong N, Madesh M, Gonzales LW et al. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J. Biol. Chem. 281(14), 9791-9800 (2006).
200. Pearce I, Heathfield KW, Pearce MJ. Valproate sodium in Huntington chorea. Arch. Neurol. 34(5), 308-309 (1977).
201. Symington GR, Leonard DP, Shannon PJ, Vajda FJ. Sodium valproate in Huntington's disease. Am. J. Psychiatry 135(3), 352-354 (1978).
202. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series. BMC Neurol. 6, 11 (2006).
203. Grove VE Jr, Quintanilla J, Devaney GT. Improvement of Huntington's disease with olanzapine and valproate. N. Engl J. Med. 343(13), 973-974 (2000).
204. US FDA, StatBite: FDA oncology drug product approvals in 2009. J. Natl Cancer Inst. 102(4), 219 (2010).
205. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10), 1247-1252 (2007).
206. Moser K, Biglan K, Ross C et al. Inaugural Huntington disease clinical research symposium organized by the Huntington study group. Neurotherapeutics 5(2), 362-375 (2008).
207. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov. Disord. 22(13), 1962-1964 (2007).
208. Spannhoff A, Kim YK, Raynal NJ et al. Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. EMBO Rep. 12(3), 238-243 (2011).
209. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 80(12), 1771-1792 (2010).
210. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenetics 1(3-4), 101-116 (2010).
211. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets (2010) (Epub ahead of print).
212. Dancik V, Seiler KP, Young DW, Schreiber SL, Clemons PA. Distinct biological network properties between the targets of natural products and disease genes. J. Am. Chem. Soc. 132(27), 9259-9261 (2010).
213. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature 441(7097), 1094-1096 (2006).
214. Zhang Y, Wang J, Chen G, Fan D, Deng M. Inhibition of sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells. Biochem. Biophys. Res. Comm. 404(2), 610-614 (2011).
215. Hisahara S, Chiba S, Matsumoto H et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc. Natl Acad. Sci. USA 105(40), 15599-15604 (2008).
216. Tursun B, Patel T, Kratsios P, Hobert O. Direct conversion of C. elegans germ cells into specific neuron types. Science 331(6015), 304-308 (2011).
217. Harper SQ, Staber PD, He X et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102(16), 5820-5825 (2005).
218. Difiglia M, Sena-Esteves M, Chase K et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA 104(43), 17204-17209 (2007).
219. Drouet V, Perrin V, Hassig R et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 65(3), 276-285 (2009).
220. Boudreau RL, Mcbride JL, Martins L et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17(6), 1053-1063 (2009).
221. Van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene. Ther. 19(7), 710-719 (2008).
222. Takahashi M, Watanabe S, Murata M et al. Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc. Natl Acad. Sci. USA 107(50), 21731-21736 (2010).
223. Pfister EL, Kennington L, Straubhaar J et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19(9), 774-778 (2009).
224. Lombardi MS, Jaspers L, Spronkmans C et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217(2), 312-319 (2009).
225. Singer O, Marr RA, Rockenstein E et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8(10), 1343-1349 (2005).
226. Rodriguez-Lebron E, Gouvion CM, Moore SA, Davidson BL, Paulson HL. Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease. Mol. Ther. 17(9), 1563-1573 (2009).
227. Eacker SM, Dawson TM, Dawson VL. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 10(12), 837-841 (2009).
228. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv. Genet. 70, 87-99 (2010).
229. Schonrock N, Ke YD, Humphreys D et al. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-b. PLoS ONE 5(6), e11070 (2010).
230. Saunders LR, Sharma AD, Tawney J et al. miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Aging (Albany NY) 2(7), 415-431 (2010).
231. Delaloy C, Liu L, Lee JA et al. MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. Cell. Stem Cell 6(4), 323-335 (2010).
232. Jing L, Jia Y, Lu J et al. MicroRNA-9 promotes differentiation of mouse bone mesenchymal stem cells into neurons by Notch signaling. Neuroreport 22(5), 206-211 (2011).
233. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008).
234. Vilardo E, Barbato C, Ciotti M, Cogoni C, Ruberti F. MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons. J. Biol. Chem. 285(24), 18344-18351 (2010).
235. Long JM, Lahiri DK. MicroRNA-101 downregulates Alzheimer's amyloid-b precursor protein levels in human cell cultures and is differentially expressed. Biochem. Biophys. Res. Comm. 404(4), 889-895 (2011).
236. Noonan EJ, Place RF, Pookot D et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28(14), 1714-1724 (2009).
237. Lize M, Pilarski S, Dobbelstein M. E2F1- inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell. Death Differ. 17(3), 452-458 (2010).
238. Gao J, Wang WY, Mao YW et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466(7310), 1105-1109 (2010).
239. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27(1), 59-65 (2009).
240. Zhang H, Yang B, Mu X et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse CNS. Mol. Ther. DOI: 10.1038/mt.2011.98 (2011) (Epub ahead of print).
241. Xie J, Xie Q, Zhang H et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 19(3), 526-535 (2011).
242. Miyake N, Miyake K, Yamamoto M, Hirai Y, Shimada T. Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res. 1389, 19-26 (2011).
243. Kumar P, Wu H, Mcbride JL et al. Transvascular delivery of small interfering RNA to the CNS. Nature 448(7149), 39-43 (2007).
244. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-345 (2011).
245. Pulford B, Reim N, Bell A et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS ONE 5(6), e11085 (2010).
246. Martin L, Latypova X, Terro F. Post-translational modifications of t protein: implications for Alzheimer's disease. Neurochem. Int. 58(4), 458-471 (2011).
247. Gong B, Chen F, Pan Y et al. SCFFbx2-E3-ligase-mediated degradation of BACE1 attenuates Alzheimer's disease amyloidosis and improves synaptic function. Aging Cell 9(6), 1018-1031 (2010).
248. Kim SH, Lu HF, Alano CC. Neuronal sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS ONE 6(3), e14731 (2011).
249. Mostoslavsky R, Chua KF, Lombard DB et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124(2), 315-329 (2006).